Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Medicine, Genetics, Oncology +11

Gefitinib-Sensitizing <i>EGFR</i> Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Raffaella Sordella, Daphne W. Bell, Daniel A. Haber et al. · Science · 2004 · 1.6K citations

Medicine, Oncology, Pharmacology +17

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Shyamala Maheswaran, Lecia V. Sequist, Sunitha Nagrath et al. · New England Journal of Medicine · 2008 · 1.6K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald et al. · Nature Medicine · 2016 · 999 citations · Full text

Medicine, Cancer Biology, Oncology +15